-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$54.5023% Upside
Avidity Biosciences, Inc. Frequently Asked Questions
-
What analysts cover Avidity Biosciences, Inc.?
Avidity Biosciences, Inc. has been rated by research analysts at Goldman Sachs, Wells Fargo in the past 90 days.